Thus, impairment in the regulation of S1P production accompanied by metabolic imbalance in ceramide salvage pathway could play a role in increased resistance to cytostatic effects of vemurafenib in BRAF mutant colon cancer cells. Here, BRAF is linked to malignant colon neoplasm.